IMMUNE ALGORITHMICS

OXFORD UNIVERSITY INNOVATION SPONSORS THE PLANTING OF A TREE IN Wytham Woods IN HONOUR OF OIA'S LAUNCH

9/10/2019

Coinciding with OIA's first anniversary this past September 25th, Oxford University planted a 4-year old small beech tree in honour of Oxford Immune Algorithmics (OIA) at the Oxford University premises in Wytham Woods, Oxford, UK where a plaque dedicated to OIA was unveiled. The tree will be taken care of for 15 years after which the plaque will be placed on the base of the tree for the hundreds of years that the tree will hopefully live and for next generations to take care. This is an initiative to create awareness and help replant an area of the woods.

Young trees like these ones can absorb CO2 much faster than larger trees as their metabolism is faster between 4 and 15 years old. Our ambitious goal at OIA for the next 15 years is to become the leaders in healthcare technology and offer an affordable scalable solution to help cure all curable human diseases. Helping plant the tree were personnel from Oxford University Innovation and OIA, including OIA's CEO Dr. Hector Zenil. OIA is honoured to have received this distinction from the 8 startups and spinouts from Oxford University that launch in average every year.

OIA Has been INVITED to pitch at bioseed 2020

6/10/2019

OIA will be at the the early stage life sciences investment event to be held at Level39 in Canary Wharf, London, January 20, 2020.

OIA ATTENDING GIANT Health Europe’s largest festival of health tech innovation

6/10/2019

On the 15-16 October 2019, OIA is attending The Global Innovation and New Technology Health Event at the Chelsea Football Club Stadium in London where it is showcased the leading health tech startups from around the world.

FURTHER validation of OIA's METHODS & algorithms

12/9/2019

An application of our research in causal models in molecular biology has been published today in one of the finest journals in molecular biology, Nucleic Acids Research (Oxford). This is the first meaningful application of algorithmic complexity to experimental cell biology beyond previous methods based on statistical approaches. It strengthens our position as pioneers in the area of causal knowledge discovery and it propels us forward as a validation of our work and technology.

Our paper shows how our methods identify DNA sequences holding key information about genetic regulation.

OPENING OF OUR NEW AI-POWERED BIOMEDICAL LAB IN A PRIME LOCATION IN READING, UK

21/8/2019

We have been growing at an exciting rate and we have moved offices three times already only this year. We have now opened our new AI-biomedical lab this month and we are already thinking of expanding it. We have here some pictures of how the the lab looks like today.

OUR NEW paper published in iscience (cell press) lays out the foundations of our technology TO BETTER DEAL WITH CAUSALITY IN MOLECULAR BIOLOGY & immunology to make a real impact in the future of healthcare

11/8/2019

This video explain in more accessible terms the basic ideas behind the paper.

OIA at Turing FOUNDERS TURINGFEST in EDINBURGH

23/7/2019

We are heading to #TuringFest19 in Edinburgh this August. OIA has been invited to participate in the Turing Founders event where startups and new companies meet investors.

OIA VIP GUEST AT IN-MEMORY COMPUTING SUMMIT

30/5/2019

OIA has been invited as a VIP guest to the 3rd annual In-Memory Computing Summit Europe, on June 3 & 4, at the Park Plaza Victoria in London where we will be promoting our science and technology.

@

CONNECTing with THE LOCAL COMMUNITY IN READING

17/5/2019

We were invited to introduce OIA and present our work on AI for healthcare at the Thames Valley Artificial Intelligence meetup organised by Barclays AI Frenzy and Innovation Catalyst, University of Reading.

OIA MANIFESTO TO END ALL (PREVENTABLE) HUMAN DISEASEs, TODAY!

8/5/2019

WHAT WOULD WE DO WITH 1 BILLION DOLLARS?

At Oxford Immune Algorithmics (OIA) we firmly believe that it is our obligation to do our best to promote the use of the most advanced scientific and technological tools and methods currently available in the fight against human disease. We believe that most, if not all, diseases are curable if detected soon enough, and that current science and technology can deliver this goal not sometime in the future, but today!

Unfortunately, human priorities are often lopsided. We just saw a Hollywood movie break records last month making 1 billion USD in only a week, with some people spending as much as 500 USD, according to certain sources, for a single cinema ticket. With 1 billion USD, OIA would have been able to distribute devices to about 20 million households and equip about 100 million people with a state-of-the-art AI-based device to monitor their health, which would have given us a good shot at eradicating some of the greatest health challenges that humanity has faced, such as cancer and antibiotic resistance, which if not solved can send us back to the Middle Ages.

Written in the late 1920s, this notebook records Alexander Fleming's experiments with bacteria and antibiotics (penicillin). While medicine is driven by technology some practices haven't changed much in 100 years. Today, the same screening test in a petri dish is still used to study and diagnose antibiotic resistance. OIA is disturbing old practices with modern science and new technology to help solve some of these world challenges.

At a rate of 100 million people a week we could cover the entire world population in about a year. But even 1% of that would produce enough data and traction to significantly improve human health and probably crack cancer and other leading causes of death. That money, however, is channelled to other places, not where it may mean more and have a more lasting impact. We also know that politicians, sportsmen and actors are given extraordinary public and media attention, but not scientists, who may be losing the fight against mysticism and misinformation. We can see how even diseases that were considered under control or eradicated are making a comeback due to political regression.

Unfortunately, we can do very little to dictate or influence human priorities when it comes to what people decide to fund. However, we have assembled a small but strong team that combines decades of academy and industry experience and is capable of transforming healthcare with state-of-the-art technology and science that we have introduced and continue to develop.

WHAT CAN OIA DO TO HELP SOLVE WORLD CHALLENGES?

Current medicine relies heavily on what overburdened medical staff can do. Today, medicine can be characterised as driven mostly by what we lack: doctors’ time, patients’ data, new approved drugs, lower-cost machinery, etc. We need to change this model. More precise and quantitatively and qualitatively superior objective diagnosis and prognosis is possible, but we need to get it right, and get it done. Current machine learning (ML) methods can help, and can accurately profile diseases, and even sometimes predict patient progress and outcomes. However, some of these AI methods are often not suitable for medical purposes because they do not explain why certain specific features or markers may make sense in practice, or why a particular prediction is made instead of another. Take as an example the classification of dogs and cats. A black-box ML approach may do a perfect job but when you dig a bit further you may find that the feature separating dogs from cats according to your ML application

is that all pictures of dogs were taken outdoors, and so ML concluded that grass and clouds were the best markers for classifying dogs, getting it right 100% of the time.

While medicine is still far from using even basic AI, the lack of explanations and generative models about which features and causes drive the observed data and results may hinder the adoption of these technologies in making diagnoses and decisions based on cause and effect. This problem currently prevents scientists from understanding the true causes of natural phenomena from first principles. We seek to overcome these limits by bringing brilliant minds and machines together to cooperate in delivering a new kind of model-based AI rooted in the research we have performed at the best universities (the University of Oxford, and the Karolinska Institute--the institution that awards the Nobel Prize in Physiology or Medicine).

WANTED. VISIONARIES AND REVOLUTIONARIES BUT ONLY IF COMMITTED

We have built a small but committed team: risk takers, and doers; and we try to avoid the bluffers. At OIA we aim at understanding key health markers in a vertical fashion in order to provide each patient with their own cellular and, eventually, molecular deep temporal profile, to help us help them identify causes and effects in time for super early detection by using non-traditional model-driven machine learning suitable for medical exploration that OIA owns and continues to develop. This is how OIA plans to change medicine, healthcare, and ultimately the human condition.

We've set out on a journey to revolutionise healthcare, bringing it from the equivalent of the dial-up to fibre optics by radically enhancing the way in which data is generated, understood, and exploited. There are some different paths that may be taken, and we may sometimes get off track, but you can help us get back on track and achieve our goals faster by investing in our cause or contributing in kind, as a volunteer, or as an ambassador. If our vision resonates with yours and you share our values, you should join us and help us achieve our goals

OIA INVITED AS ACADEMIC PARTNER TO COGX IN LONDON, THE FESTIVAL OF AI AND EMERGENT TECHNOLOGIES

11/4/2019

A three day festival of events on 10-12 June, 2019.

OIA INVITED TO the global ai & big data world EXPO in london, u.k. TO DELIVER A TALK ON CAUSAL MACHINE LEARNING IN HEALTHCARE

10/3/2019

Invited by the organisers, Dr. Zenil (CEO) presented our research on AI for medicine at the World Expo on AI, Big Data & IoT at the Olympia Exhibition Centre on the 25th April in London, U.K.

Jürgen Riedel (CTO), Mariana González (Quality Manager) and Jasper Riedel attended the expo, representing OIA

we presented BEFORE MORE THAN 600 DATA GEEKS at BMW's IT centre in munich, germany

10/3/2019

We were honoured to present our algorithms and novel approaches to machine learning, healthcare and personalised medicine at the Datageeks Data Day 2019 sponsored by BMW, Airbus, and AID at the impressive BMW IT Zentrum (ITZ) in Munich, Germany before a crowd of 600 people. Jürgen Riedel (CTO), and Emil Melikov (Software Development Director) from OIA attended the conference and were instrumental in its organisation.

OIA's director, Dr. Zenil, presenting at BMW's IT headquarters in Munich, 9 March 2019

SUCCESSFUL PRESENTATION AT OUR 1K PEOPLE GROUP UK-AI Innovation IN london, U.K.

31/1/2019

We had a successful meeting with our >1K people group (UK-AI Innovation) in East London to explain our most recent results in Artificial Intelligence and Machine Learning, their potential to transform academia and industry including healthcare, and also their current limitations and challenges. Subscribe to our UK-AI Innovation group led by Oxford Immune Algorithmics (OIA).

Drs. Jürgen Riedel and Hector Zenil from Oxford Immune Algorithmics and Mark Needham from Neo4j delivering talks on the state of AI, ML, and DL, use of network representations, challenges and limitations of technology.

NEWly PUBLISHED AND ACCEPTED PAPERS